Ukraine conflict leaves a hole in clinical trials enrolment in region
9 Oct 2022
Clinical trials in Ukraine and Russia have plunged by around 50% during 2022, according to the latest information examined by data analytics leader Phesi.
The number of sites in Ukraine actively enrolling patients slipped from ,1814 to 940, a drop of 48%. In Russia the reduction has been even sharper – from 3,412 to 1,638 (52%). The largest proportional fall however has occurred in Belarus. Its sites reduced by 55%, from 84 to 55.
“The drop in recruiting sites in Ukraine and in Russia sadly confirms our earlier prediction that the impact of war in the region on clinical development, and most importantly on patients, is considerable,” commented Phesi CEO and Founder Dr Gen Li.
“However, what is heartening to see is that despite the terrible situation, there is still significant clinical trial activity taking place in the four countries that we have analysed.“
Not only were a significant portion of sites in all countries continuing to enrol patients but also neighbouring Poland – host to the largest number of Ukrainian refugees – has increased overall its recruiting investigator sites by 10% from 3,473 to 3,829,
“The global COVID-19 pandemic was unable to completely stop them and neither has the war. I congratulate our colleagues on maintaining such a high level of activity and working to minimise the impact on patients,” added Gen Li.
“The war in Ukraine is moving fast and disruption will continue for some time. I urge trial sponsors to keep up their vital work and continue funding sites, even those that might be suspended, and maintain dialogue with regulators and CROs to ensure data integrity is maintained.”
Pic: Martin Lopez
